ABSTRACT
Using a syngeneic transplantable leukemia model of 615 inbred mice, named L615, we (1) compared the adoptive immunoprophylactic(AIP) effects of spleen cells from various normal dornor mice with different genetic background and from different immune-deficient mice;(2) studied the adoptive immunotherapeutic (AIT) and adoptive chemo-immunotherapeutic(ACIT) effects of immune spleen cells from those survival mice in the AIP groups;(3) analysed the antitumor activities of various murine spleen cells either nonspecifically activated in vitro or specifically induced in vivo and resensitized in vitro by MMC-treated L615 tumor cell vaccine (TCV).Our results might provide some new experimental evidences for clinical application of cancer ACI.
ABSTRACT
In the present experiment, we investigated the im munoprophylactic and immunotherapeutic effects of transferring spleen LAK cells or " LAK-88/DC " cells from 615 inbred mice against mouse leukemia. The results showed that transferring LAK cells or "LAK-88/DC" cells and injecting conditional medium for a week 21 days before L615 inoculation induced significant prophylactic effects, which cured 80% of the L615-sufferring mice. Injecting conditional medium alone was also effective, which cured 60% of the mice, While transferring LAK cells or "LAK-88/DC" cells at the same time with L615 inoculation or 1 day after L615 inoculation presented no apparent therapeutic effect. However, when combined with cyclophosphamide (CY) chemotherapy, the transfer of LAK cells or "LAK-88/DC " cells 5 days after L615 inoculation could prolong the mean survival time and even cured 25%-28.6% of the advanced L615 leukemic mice.